After nearly three months of hard work, the Shengyi technology R&D and product registration team has successfully developed a hybrid capture immunofluorescence method for new coronavirus nucleic acid detection reagents, successfully passed the registration verification and clinical evaluation, and finally obtained the three-category medical device registration certificate (registration certificate) Number: National Machinery Note 20203400298). The product has the advantages of more efficient and convenient operation, and it is expected to contribute to the prevention and control of the new crown virus epidemic.